Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Prochazka, KT; Uhl, B.
Bcl2 inhibitor venetoclax +/- Anti-CD20: what do deep remissions mean?
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-021-00778-2
Web of Science
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Prochazka Katharina
- Co-authors Med Uni Graz
- Uhl Barbara
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In recent years, treatment of patients exhibiting chronic lymphocytic leukemia has changed extensively due to advances in the development of targeted therapies. The Bcl-2 inhibitor venetoclax demonstrated outstanding results when used in mono- as well as combination therapy. Minimal residual disease (MRD) measurement has become an important endpoint in most studies and shows high prognostic potential. With upcoming combination strategies, the role of MRD measurement has also increased and is likely to become a routine marker in future clinical practice.
- Find related publications in this database (Keywords)
- Chronic lymphocytic leukemia
- Venetoclax
- Bcl2 inhibitor
- Remission
- Minimal residual disease